Parkinson's disease in Sweden-resource use and costs by severity.


Journal

Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336

Informations de publication

Date de publication:
Nov 2021
Historique:
revised: 24 06 2021
received: 28 05 2021
accepted: 01 07 2021
pubmed: 14 7 2021
medline: 26 11 2021
entrez: 13 7 2021
Statut: ppublish

Résumé

To estimate resource use and costs, including direct and indirect costs, in relation to levels of severity in individuals with Parkinson's disease (PD) in a Swedish setting. Patients with idiopathic PD registered in the National Parkinson's Disease Patient Registry (PARKreg), with registrations of Hoehn and Yahr (H&Y) and "off time" in the Skåne Region, were included. Annual costs of healthcare contacts, drugs, formal and informal care, and productivity loss associated with PD were estimated using data from PARKreg linked with regional and national healthcare registers between 2013 and 2019. In total, 960 patients and 1324 observations (patient-years) were included. Total average cost per patient-year was SEK 168,982 (EUR 15,958) and ranged from SEK 62,404 (EUR 5893) for H&Y stage I to SEK 1,056,324 (EUR 99,755) in H&Y stage V. The dominating part of total costs for early stages were indirect costs accounting for 50-60% while formal care made up for 55% and 81% of total costs in H&Y IV and V, respectively. Total mean costs for formal care, informal care, and productivity loss also increased with increasing off-time. Advanced and late stages of PD are associated with significant societal costs as patients in those stages often require resource-intensive and costly formal care. Thus, there are potential savings to be made, by optimizing the pharmacological and surgical symptomatic treatment of patients with advanced disease.

Identifiants

pubmed: 34254292
doi: 10.1111/ane.13502
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

592-599

Subventions

Organisme : AbbVie
Organisme : Medtronic
Organisme : Nordic Infucare

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953.
Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord. 2000;15(6):1112-1118.
Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord. 2002;17(6):1213-1220.
Tamás G, Gulácsi L, Bereczki D, et al. Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary. PLoS One. 2014;9(9):e107704.
von Campenhausen S, Winter Y, Rodrigues e Silva A, et al. Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol. 2011;21(2):180-191.
Findley LJ, Wood E, Lowin J, Roeder C, Bergman A, Schifflers M. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ. 2011;14(1):130-139.
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Drug and treatment costs in Parkinson's disease patients in Sweden. Acta Neurol Scand. 2012;125(2):142-147.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442.
Southern Healthcare Region. Regionala priser och ersättningar för södra sjukvårdsregionen 2019. 2019.
Swedish Association of Local Authorities and Regions. Kostnad per brukare - vård och omsorg om äldre och personer md funktionsnedsättning 2014. 2014.
Rådet för främjande av kommunala analyser (RKA). Kolada database. 2020; Available from: https://www.kolada.se/.
Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 2005.
Ekonomifakta. Sociala avgifter över tid. 2019 [cited 2020-03-09; Available from: http://www.Ekonomifakta. se/Fakta/Skatter/Skatt-pa-arbete/Sociala-avgifter-over-tid/.
Statistiska Centralbyrån. Genomsnittlig månadslön 2019, kronor efter sector, Yrke (SSYK. 2012), kön, ålder och år. [cited 2020-03-09; Available from: http://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__AM__AM0110__AM0110A/LonYrkeAlder4A/.
Svenska Neuroregister. Årsrapport 2019. 2020.
Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics. 2005;23(8):817-836.
Winter Y, von Campenhausen S, Reese JP, et al. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis. 2010;7(6):365-372.

Auteurs

Frida Hjalte (F)

The Swedish Institute for Health Economics, Lund, Sweden.

Jenny M Norlin (JM)

The Swedish Institute for Health Economics, Lund, Sweden.

Klas Kellerborg (K)

The Swedish Institute for Health Economics, Lund, Sweden.

Per Odin (P)

Department of Neurology, Rehabilitation Medicine, Memory Disorders, and Geriatrics, Skåne University Hospital, Malmö, Sweden.
Department of Clinical Sciences Lund, Restorative Parkinson Unit, Division of Neurology, Lund University, Lund, Sweden.
SWEPAR-net, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH